Statistics at a Glance

At a Glance

Estimated New Cases in 2020 6,150

% of All New Cancer Cases 0.3%

Estimated Deaths in 2020 1,520

% of All Cancer Deaths 0.3%

5-Year
Relative Survival

68.8% 2010–2016
Year Rate of New Cases — SEER 9 Rate of New Cases — SEER 13 Death Rate — U.S. 5-Year Relative Survival — SEER 9
Observed Modeled Trend Observed Modeled Trend Observed Modeled Trend Observed Modeled Trend
1975 0.93 0.97 - - 0.66 0.64 31.13% 44.52%
1976 1.08 1.01 - - 0.64 0.64 38.60% 45.41%
1977 1.10 1.04 - - 0.63 0.64 51.62% 46.29%
1978 1.03 1.07 - - 0.64 0.64 51.59% 47.18%
1979 1.02 1.11 - - 0.62 0.63 46.14% 48.05%
1980 1.12 1.15 - - 0.64 0.63 49.28% 48.92%
1981 1.24 1.19 - - 0.61 0.63 51.71% 49.79%
1982 1.23 1.23 - - 0.64 0.62 54.21% 50.65%
1983 1.29 1.27 - - 0.64 0.62 46.87% 51.50%
1984 1.32 1.31 - - 0.62 0.62 46.47% 52.34%
1985 1.30 1.32 - - 0.62 0.62 56.33% 53.18%
1986 1.30 1.33 - - 0.59 0.61 54.07% 54.01%
1987 1.32 1.34 - - 0.62 0.61 55.49% 54.83%
1988 1.40 1.34 - - 0.58 0.61 53.40% 55.64%
1989 1.62 1.35 - - 0.62 0.61 55.11% 56.45%
1990 1.42 1.36 - - 0.62 0.60 56.06% 57.24%
1991 1.38 1.37 - - 0.59 0.58 61.62% 58.03%
1992 1.35 1.38 1.45 1.43 0.57 0.57 57.24% 58.81%
1993 1.26 1.39 1.41 1.45 0.55 0.55 60.22% 59.58%
1994 1.19 1.40 1.35 1.46 0.53 0.53 58.54% 60.34%
1995 1.50 1.40 1.57 1.48 0.53 0.53 61.99% 61.09%
1996 1.39 1.41 1.53 1.49 0.53 0.52 68.14% 61.83%
1997 1.33 1.42 1.46 1.50 0.50 0.52 65.10% 62.56%
1998 1.46 1.43 1.65 1.52 0.53 0.51 64.02% 63.29%
1999 1.31 1.44 1.38 1.53 0.49 0.51 65.88% 64.00%
2000 1.40 1.45 1.50 1.55 0.50 0.50 62.93% 64.70%
2001 1.46 1.46 1.56 1.57 0.50 0.49 62.61% 65.40%
2002 1.50 1.47 1.61 1.58 0.50 0.49 69.03% 66.08%
2003 1.43 1.48 1.50 1.60 0.49 0.48 65.77% 66.76%
2004 1.56 1.49 1.69 1.61 0.47 0.48 67.52% 67.42%
2005 1.58 1.50 1.69 1.63 0.49 0.47 67.95% 68.07%
2006 1.45 1.51 1.62 1.64 0.46 0.47 70.27% 68.72%
2007 1.52 1.52 1.73 1.66 0.47 0.46 71.26% 69.35%
2008 1.50 1.53 1.66 1.68 0.46 0.46 71.90% 69.98%
2009 1.47 1.54 1.64 1.69 0.45 0.45 69.35% 70.59%
2010 1.46 1.55 1.64 1.71 0.45 0.45 74.36% 71.20%
2011 1.78 1.56 1.90 1.73 0.44 0.44 71.43% 71.79%
2012 1.48 1.57 1.71 1.74 0.43 0.44 69.63% 72.38%
2013 1.62 1.58 1.79 1.76 0.43 0.43 - 72.95%
2014 1.60 1.59 1.84 1.78 0.44 0.44 - 73.52%
2015 1.49 1.60 1.71 1.80 0.45 0.44 - 74.07%
2016 1.69 1.61 1.88 1.81 0.44 0.44 - 74.62%
2017 1.64 1.62 1.70 1.83 0.43 0.44 - 75.16%
2018 - - - - 0.45 0.44 - 75.69%

New cases come from SEER 13. Deaths come from U.S. Mortality.
All Races, Both Sexes. Rates are Age-Adjusted.
Modeled trend lines were calculated from the underlying rates using the Joinpoint Trend Analysis Software.

New cases are also referred to as incident cases in other publications. Rates of new cases are also referred to as incidence rates.


Rate of New Cases and Deaths per 100,000: The rate of new cases of acute lymphocytic leukemia was 1.7 per 100,000 men and women per year. The death rate was 0.4 per 100,000 men and women per year. These rates are age-adjusted and based on 2013–2017 cases and 2014–2018 deaths.

Lifetime Risk of Developing Cancer: Approximately 0.1 percent of men and women will be diagnosed with acute lymphocytic leukemia at some point during their lifetime, based on 2015–2017 data.

Prevalence of This Cancer: In 2017, there were an estimated 100,012 people living with acute lymphocytic leukemia in the United States.

Did You Know? Video Series

Survival Statistics

How Many People Survive 5 Years Or More after Being Diagnosed with Acute Lymphocytic Leukemia?

Relative survival is an estimate of the percentage of patients who would be expected to survive the effects of their cancer. It excludes the risk of dying from other causes. Because survival statistics are based on large groups of people, they cannot be used to predict exactly what will happen to an individual patient. No two patients are entirely alike, and treatment and responses to treatment can vary greatly.

68.8%

5-Year
Relative Survival

68.8%

Based on data from SEER 18 2010–2016. Gray figures represent those who have died from acute lymphocytic leukemia. Green figures represent those who have survived 5 years or more.

New Cases and Deaths

How Common Is This Cancer?

Rank Common Types of Cancer Estimated New
Cases 2020
Estimated
Deaths 2020
1. Breast Cancer (Female) 276,480 42,170
2. Lung and Bronchus Cancer 228,820 135,720
3. Prostate Cancer 191,930 33,330
4. Colorectal Cancer 147,950 53,200
5. Melanoma of the Skin 100,350 6,850
6. Bladder Cancer 81,400 17,980
7. Non-Hodgkin Lymphoma 77,240 19,940
8. Kidney and Renal Pelvis Cancer 73,750 14,830
9. Uterine Cancer 65,620 12,590
10. Leukemia 60,530 23,100
- - -
Acute Lymphocytic Leukemia 6,150 1,520

Acute lymphocytic leukemia represents 0.3% of all new cancer cases in the U.S.

0.3%

In 2020, it is estimated that there will be 6,150 new cases of acute lymphocytic leukemia and an estimated 1,520 people will die of this disease.

Who Gets This Cancer?

Acute lymphocytic leukemia is most common in children, adolescents, and young adults, or those 15 to 39 years of age. ALL is most common in Hispanics and Whites. The rate of new cases of acute lymphocytic leukemia was 1.7 per 100,000 men and women per year based on 2013–2017 cases, age-adjusted.

Rate of New Cases per 100,000 Persons by Race/Ethnicity & Sex: Acute Lymphocytic Leukemia (ALL)
Males
All Races 2.0
White 2.2
Black 1.1
Asian/Pacific Islander 1.6
American Indian/Alaska Native 1.8
Hispanic 2.9
Non-Hispanic 1.7
Females
All Races 1.5
White 1.6
Black 0.9
Asian/Pacific Islander 1.4
American Indian/Alaska Native 1.5
Hispanic 2.2
Non-Hispanic 1.3

SEER 21 2013–2017, Age-Adjusted

Percent of New Cases by Age Group: Acute Lymphocytic Leukemia
Age Range Percent of New Cases
<20 53.4%
20–34 10.9%
35–44 6.0%
45–54 7.4%
55–64 9.0%
65–74 7.4%
75–84 4.3%
>84 1.8%

Acute lymphocytic leukemia is most frequently diagnosed among people aged <20.

Median Age
At Diagnosis

17

SEER 21 2013–2017, All Races, Both Sexes

Who Dies From This Cancer?

The death rate was 0.4 per 100,000 men and women per year based on 2014–2018 deaths, age-adjusted.

Death Rate per 100,000 Persons by Race/Ethnicity & Sex: Acute Lymphocytic Leukemia (ALL)
Males
All Races 0.5
White 0.6
Black 0.3
Asian/Pacific Islander 0.4
American Indian/Alaska Native 0.6
Hispanic 0.8
Non-Hispanic 0.5
Females
All Races 0.4
White 0.4
Black 0.3
Asian/Pacific Islander 0.3
American Indian/Alaska Native 0.5
Hispanic 0.6
Non-Hispanic 0.3

U.S. 2014–2018, Age-Adjusted

Percent of Deaths by Age Group: Acute Lymphocytic Leukemia
Age Range Percent of Deaths
<20 13.2%
20–34 13.7%
35–44 8.1%
45–54 10.4%
55–64 15.0%
65–74 16.6%
75–84 14.3%
>84 8.7%

The percent of acute lymphocytic leukemia deaths is highest among people aged 65–74.

Median Age
At Death

58

U.S. 2014–2018, All Races, Both Sexes

Trends in Rates

Changes Over Time

Keeping track of new cases, deaths, and survival over time (trends) can help scientists understand whether progress is being made and where additional research is needed to address challenges, such as improving screening or finding better treatments.

Using statistical models for analysis, age-adjusted rates for new acute lymphocytic leukemia cases have been rising on average 0.6% each year over 2008–2017. Age-adjusted death rates have been stable over 2009–2018. 5-year relative survival trends are shown below.

Interactive Statistics with SEER*Explorer

With SEER*Explorer, you can...
  • Create custom graphs and tables
  • Download data and images
  • Share links to results

SEER*Explorer is an interactive website that provides easy access to a wide range of SEER cancer statistics. It provides detailed statistics for a cancer site by gender, race, calendar year, age, and for a selected number of cancer sites, by stage and histology.

Explore Additional Acute Lymphocytic Leukemia Statistics

More About This Cancer

Cancer and the Blood

Figure: Blood Cells Maturing from Stem Cells

Figure: Stem cells maturing into one of three types of mature blood cells: red blood cells, platelets, and white blood cells. Precursor cells are also shown: stem cells, myeloid blasts, lymphoid stem cells, and lymphoid blasts.

Leukemia is cancer that starts in the tissue that forms blood. Most blood cells develop from cells in the bone marrow called stem cells. In a person with leukemia, the bone marrow makes abnormal white blood cells. The abnormal cells are leukemia cells. Unlike normal blood cells, leukemia cells don't die when they should. They may crowd out normal white blood cells, red blood cells, and platelets. This makes it hard for normal blood cells to do their work. The four main types of leukemia are:

There is no standard staging system for leukemia. The disease is described as untreated, in remission, or recurrent.

Additional Information

More Information

Here are some resources for learning more about leukemia.

References

All statistics in this report are based on statistics from SEER and the Centers for Disease Control and Prevention's National Center for Health Statistics. Most can be found within SEER*Explorer.

Suggested Citation

All material in this report is in the public domain and may be reproduced or copied without permission; citation as to source, however, is appreciated.

SEER Cancer Stat Facts: Acute Lymphocytic Leukemia. National Cancer Institute. Bethesda, MD, https://seer.cancer.gov/statfacts/html/alyl.html

These stat facts focus on population statistics that are based on the U.S. population. Because these statistics are based on large groups of people, they cannot be used to predict exactly what will happen to an individual patient. To see tailored statistics, browse SEER*Explorer. To see statistics for a specific state, go to the State Cancer Profiles.

The statistics presented in these stat facts are based on the most recent data available, most of which can be found in SEER*Explorer. In some cases, different year spans may be used.

Estimates of new cases and deaths for 2020 are projections made by the American Cancer Society (ACS), based on earlier reported data.

Cancer is a complex topic. There is a wide range of information available. These stat facts do not address causes, symptoms, diagnosis, treatment, follow-up care, or decision making, although links are provided to information in many of these areas.